Activist investor Shah Capital is renewing its pressure campaign against Novavax (NVAX) as it looks to vote against the re-election of the company’s board nominees and its executive ​compensation ...

By Sneha S K and Sriparna Roy April 8 (Reuters) - Activist investor Shah Capital plans to vote against the re-election of ...

Shah Capital, which has agitated for change at the vaccine maker for years, is calling on fellow shareholders to end what it ...

In the latest close session, Novavax (NVAX) was up +1.31% at $8.53. The stock outperformed the S&P 500, which registered a daily gain of 0.62%. Meanwhile, the Dow gained 0.58%, and the Nasdaq, a ...

"Your tenure has overseen a DESTRUCTION of shareholder value—a direct result of chronic operational shortcomings and failures ...

Over the last six months, Novavax shares have sunk to $8.21, producing a disappointing 7.7% loss - worse than the S&P 500’s 2 ...

Chief among its criticisms is Novavax's failure to build sales of its protein-based COVID-19 vaccine Nuvaxovid/Covovax, a ...

Shah Capital plans “against” votes on directors and say-on-pay, while seeking to sway ISS and Glass Lewis rather than running ...

An activist investor is putting pressure on Gaithersburg vaccine maker Novavax to make changes, for the third time in two ...

Shah Capital, which owns 9% of Novavax and is its second-largest shareholder, sent a letter to the company renewing pressure ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

Following its emergency authorization last month, just 7,300 doses of Novavax's COVID-19 vaccine have been administered to Americans across the country, newly updated data from the Centers for Disease ...